Cargando…
In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study
BACKGROUND: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI). Glycoprotein IIb/IIIa inhibitors are used in the treatment of no-reflow (NR), but their role to prevent it is unproven. OBJECTIVE: To e...
Autores principales: | Lago, Igor Matos, Novaes, Gustavo Caires, Badran, André Vannucchi, Pavão, Rafael Brolio, Barbosa, Ricardo, de Figueiredo, Geraldo Luiz, Lima, Moysés de Oliveira, Haddad, Jorge Luiz, Schmidt, André, Marin, José Antônio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cardiologia - SBC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137384/ https://www.ncbi.nlm.nih.gov/pubmed/27982267 http://dx.doi.org/10.5935/abc.20160149 |
Ejemplares similares
-
Effects of tirofiban on the reperfusion-related no-reflow in rats with acute myocardial infarction
por: Liu, Xiao, et al.
Publicado: (2013) -
Aspirin plus verapamil relieves angina and perfusion abnormalities in patients with coronary microvascular dysfunction and Chagas disease: a pilot non-randomized study
por: Pavão, Rafael Brolio, et al.
Publicado: (2021) -
Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon
por: Qin, Tao, et al.
Publicado: (2013) -
A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention
por: Zeng, Qian, et al.
Publicado: (2020) -
Tirofiban-induced thrombocytopenia
por: Wang, Jun, et al.
Publicado: (2023)